Revolution of Alzheimer Precision Neurology Passageway of Systems Biology and Neurophysiology

Manuscript Number: 

17-9932

Author(s): 
Claudio Babiloni, Filippo Baldacci, Keith L. Black, Arun L.W. Bokde, René S. Bun, Francesco Cacciolam, Enrica Cavedo, Patrizia A. Chiesa, Olivier Colliot, Cristina-Maria Coman, Bruno Dubois, Andrea Duggento, Stanley Durrleman, Maria Teresa Ferretti, Francesco Garaci, Remy Genthon, Nathalie George, Marie-Odile Habert, Harald Hampel, Karl Herholz, Maya Koronyo-Hamaoui, Yosef Koronyo, Foudil Lamari, Todd Langevin, Stéphane Lehéricy, Simone Lista, Jean Lorenceau, Christian Neri, Robert Nisticò, Francis Nyasse-Messene, Craig W. Ritchie, Simone Rossi, Emiliano Santarnecchi, Olaf Sporns, Nicola Toschi, Steven R. Verdooner, Andrea Vergallo, Nicolas Villain, Erfan Younesi

Disclosures

Claudio Babiloni

  • Nothing to Disclose

Filippo Baldacci

  • Nothing to Disclose

Keith L. Black

  • Equity:
    equity ownership in Neurovision Inc.

Arun L.W. Bokde

  • Nothing to Disclose

René S. Bun

  • Nothing to Disclose

Francesco Cacciolam

  • Nothing to Disclose

Enrica Cavedo

  • Nothing to Disclose

Patrizia A. Chiesa

  • Nothing to Disclose

Olivier Colliot

  • Lecture Fees:
    He has received lecture fees from Roche
    Grants
    • Agency: 
      Air Liquide Medical Systems
      Dates: 
      2016
    • Agency: 
      Qynapse SAS
      Dates: 
      2017
    • Agency: 
      MyBrainTechnologies SAS
      Dates: 
      2016-2019

Cristina-Maria Coman

  • Nothing to Disclose

Bruno Dubois

  • Consulting Fees:
    Bruno DUBOIS has received consultant fees from Lilly, Boehringer Ingelheim and has been paid for advisory boards from Biogen.
    Grants
    • Agency: 
      Roche
      Dates: 
      2010
    • Agency: 
      Merck
      Dates: 
      2014

Andrea Duggento

  • Nothing to Disclose

Stanley Durrleman

  • Patents/Royalties
    "A method for determining the temporal progression of a biological phenomenon and associated methods and devices'' submitted under reference PCT/IB2016/052699 US Patent "Methods for Obtaining Continuous Trajectories from Discrete Anatomical Shapes'" MBF Ref. 026389-9045-US00, Utah Ref. U-5184

Maria Teresa Ferretti

  • Nothing to Disclose

Francesco Garaci

  • Nothing to Disclose

Remy Genthon

  • Nothing to Disclose

Nathalie George

  • Nothing to Disclose

Marie-Odile Habert

  • Consulting Fees:
    Lilly
    Lecture Fees:
    LILLY: consulting fee for a training course

Harald Hampel

  • Consulting Fees:
    Infequent scientific consultant and/or speaker and/or attended scientific advisory boards of Jung Diagnostics, Cytox Ltd., Axovant, Anavex, Takeda and Zinfandel, GE Healthcare, Eli Lilly and company, Oryzon, Roche
    Lecture Fees:
    Infrequent speaker supported by Axovant, Roche, Eisai
    Patents/Royalties
    I am co-inventor in the following patents and have received no royalties: - In vitro multiparameter determination method for the Diagnosis and early diagnosis of neurodegenerative disorders Patent number: 8916388 - In vitro procedure for diagnosis and early diagnosis of neurodegenerative diseases Patent number: 8298784 - Neurodegenerative Markers for Psychiatric Conditions Publication number: 20120196300 - IN VITRO MULTIPARAMETER DETERMINATION METHOD FOR THE DIAGNOSIS AND EARLY DIAGNOSIS OF NEURODEGENERATIVE DISORDERS Publication number: 20100062463 - IN VITRO METHOD FOR THE DIAGNOSIS AND EARLY DIAGNOSIS OF NEURODEGENERATIVE DISORDERS Publication number: 20100035286 - In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Publication number: 20090263822 - In vitro method for the diagnosis of neurodegenerative diseases Patent number: 7547553 - CSF Diagnostic in Vitro Method for Diagnosis of Dementias and Neuroinflammatory Diseases Publication number: 20080206797 - In Vitro Method For the Diagnosis of Neurodegenerative Diseases Publication number: 20080199966 - Neurodegenerative Markers for Psychiatric Conditions Publication number: 20080131921

Karl Herholz

  • Grants
    • Agency: 
      GEHC, GSK
      Dates: 
      2013, 2016

Yosef Koronyo

  • Consulting Fees:
    Consultant, Neurovision Imaging, LLC
    Equity:
    <2.5% stock
    Patents/Royalties
    Patent US 9,839,699 B2

Maya Koronyo-Hamaoui

  • Consulting Fees:
    Consultant, Neuovision Imaging, LLC
    Equity:
    <2.5% stock owner
    Patents/Royalties
    Patent US 9,839,699 B2

Foudil Lamari

  • Nothing to Disclose

Todd Langevin

  • Equity:
    Stock options in Functional Neuromodulation.

Stéphane Lehéricy

  • Nothing to Disclose

Simone Lista

  • Lecture Fees:
    Lecture honoraria from Roche

Jean Lorenceau

  • Nothing to Disclose

Christian Neri

  • Nothing to Disclose

Robert Nisticò

  • Nothing to Disclose

Francis Nyasse-Messene

  • Nothing to Disclose

Craig W. Ritchie

  • Consulting Fees:
    I have provided consultancy services over the last 2 years for the following companies who have an interest in developing compounds for the management of neurodegenerative diseases: Roche, Kywoa Kirin, Nutricia, Pfizer, Merck, Eisai, Lundbeck and Actinogen. I am also academic lead for a public/private IMI-funded partnership (EPAD - European Prevention of Alzheimer's Dementia) Programme. The non-academic partners in that are: Amgen , ACImmune, Janssen, Novartis, Lundbeck, Pfizer, Takeda, Eisai, Boeringher Ingleheim, Synapse, Roche Diagnostics, Alzheimer's Europe, Ixico and Aridhia.
    Lecture Fees:
    I have received fees from Nutricia for chairing a symposium at AAIC in London in 2017.
    Grants
    • Agency: 
      Merck
      Dates: 
      2017-2020

Simone Rossi

  • Nothing to Disclose

Emiliano Santarnecchi

  • Nothing to Disclose

Olaf Sporns

  • Nothing to Disclose

Nicola Toschi

  • Nothing to Disclose

Steven R. Verdooner

  • Equity:
    Equity in NeuroVision
    Sponsors:
    CEO of NeuroVision

Andrea Vergallo

  • Nothing to Disclose

Nicolas Villain

  • Nothing to Disclose

Erfan Younesi

  • Nothing to Disclose